NanoVibronix (NASDAQ:NAOV) Share Price Passes Below Fifty Day Moving Average of $0.95

NanoVibronix, Inc. (NASDAQ:NAOV)’s share price passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $0.95 and traded as low as $0.75. NanoVibronix shares last traded at $0.80, with a volume of 33,459 shares changing hands.

NanoVibronix Stock Performance

The stock has a 50 day moving average of $0.95 and a 200-day moving average of $1.02. The firm has a market capitalization of $2.23 million, a P/E ratio of -0.38 and a beta of 1.25.

Institutional Investors Weigh In On NanoVibronix

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of NanoVibronix by 53.7% during the first quarter. Vanguard Group Inc. now owns 651,262 shares of the company’s stock valued at $755,000 after buying an additional 227,454 shares during the period. Geode Capital Management LLC increased its position in shares of NanoVibronix by 5.5% during the fourth quarter. Geode Capital Management LLC now owns 218,442 shares of the company’s stock valued at $54,000 after buying an additional 11,344 shares during the period. State Street Corp increased its position in shares of NanoVibronix by 32.1% during the first quarter. State Street Corp now owns 125,390 shares of the company’s stock valued at $145,000 after buying an additional 30,500 shares during the period. Finally, Armistice Capital LLC bought a new stake in shares of NanoVibronix during the third quarter valued at about $57,000. 16.39% of the stock is currently owned by institutional investors.

About NanoVibronix

NanoVibronix, Inc, through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.